Sylvio is the Scientific programs coordinator at Adebiotech, the Paris-based transdisciplinary biotechnology independent think tank since October 2018. Starting with an academic background in cellular immunology, he gained confirmed >20 years experience in Bioproduction and Purification of therapeutic proteins (and gene therapy vectors). He acquired strong technical and strategic business development experience in various scientific domains (chromatography, cell culture, molecular biology, high-end instrumentation, proteomics, analytical services) through management positions at PALL Life Sciences, Ciphergen Biosystems, Life Technologies, Merck/VWR, BioSepra/Sepracor Inc

Before joining Adebiotech he acted as a strategy consultant for international biotech organizations . Sylvio is a multicultural person and has been a frequent speaker and moderator at various academic and industrial BioProcessing related conferences worldwide.

Denis Chéreau est le Directeur Général d’IMPROVE. Il a participé au lancement de LYVEN startup dans le monde de la production d’enzymes et de métabolites par fermentation en milieu solide. Il a ensuite passé près de 15 ans dans le secteur de l’amidonnerie / glucoserie sur des postes de directions techniques ou de directions d’usines en France et aux USA. Depuis 8 ans au sein d’IMPROVE il a contribuer à développer une offre de prestation de service en R&D sur la thématique des protéines alternatives pour plus de 400 sociétés dans le monde.

Sune is a biotechnologist with more than 10 years of experience with research and innovation in academia and industry leading cross-functional and cross-sectorial project teams spanning basic science, early-stage R&D and product development. His scientific areas of expertise include enzyme mechanisms, protein engineering, high throughput screening and quantitative microscopy. Sune is particularly interested in the problem of climate change mitigation and is engaged in product development, project scoping and technology scouting activities in this area.

Prior to joining Novozymes, Sune was a Postdoc at UC Berkeley where he studied signaling proteins involved in immune cell activation and cancer. Sune holds a PhD in chemistry from the University of Copenhagen and a master’s degree in nanoscience from the University of Copenhagen.

Philippe holds a PhD in Molecular Biology from the Université Libre de Bruxelles (ULB) obtained in 1993 and a Master in Management de l’Innovation from HEC Saint Louis (Brussels, Belgium) obtained in 1995.

In 1995-1996 Philippe did a post-doctoral research at the University of Edinburgh (UK).  During this research he discovered using mouse model the function of the alpha-fetoprotein the major embryonic plasma protein in mammalian development.  

During his academic research career he was involved has an inventor in the development of a portfolio of genetic selection patented technologies. 

One of these technologies belonging to ULB was licensed to Life technologies and is on the market since 1995 it is today a standard in DNA assembly method: Gateway technology, TOPO cloning. Other technologies were licensed to Sanofi-Pasteur, GSK and Merck to improve biopharmaceutical production.

Since 2013 Philippe is the founder and Chief Scientific Officer of Syngulon a startup focusing on genetic innovations to improve the biocontrol of microbial population using bacteriocins (antimicrobial peptides). Philippe has established several partnerships for the company with academics and industries. 

Danielle Lando est titulaire d’un doctorat d’état obtenu à l’Institut Pasteur de Paris pour la recherche en virologie. Elle a effectué sa carrière dans l’industrie pharmaceutique où elle a exercé des fonctions de chercheur en pharmacologie cellulaire et moléculaire avant de prendre la responsabilité des biotechnologies au sein de Roussel Uclaf devenu Sanofi. Elle a œuvré pour des rapprochements entre son entreprise et le secteur académique en soutenant des projets collaboratifs. Elle a été membre nommé au Comité National du CNRS de 1995 à 2000.

Depuis 2001, elle exerce des activités scientifiques bénévoles au sein d’Adebiotech, association dont elle est actuellement Vice-Présidente.

After completing her Ph.D. in Organic Synthesis at the University of Caen (France), Juliette conducted an Industrial Post-doctoral fellowship in Asymmetric Chemocatalysis at Zeneca Life Science Molecules in UK. In 1999, she joined Avecia (UK) as R&D Team Manager focusing on New Technology Platforms involving chemo- and bio-catalysis.

In 2006, she joined Seqens once the newly joint-venture was created with the industrial biotechnology company Protéus (France).

In 2009, she became R&D Manager focusing on some ‘Key Technologies’ process development. She then became Head of Biocatalysis for Pharma Synthesis.

In 2012, she was appointed General Manager of Protéus.

Today, she values her 25 years’ experience in the field of chemistry & biocatalysis to leverage R&D Paternerships.

After an agricultural engineer School in France (Lasalle Beauvais), Alexis RANNOU joined ARD for activities in R&D to extract non digestible sugar for surfactant application (1991-1995). He was after in charge of ARD’s pilot plant (1995-1997).

In 1997 he joined the Soliance company (daughter company of ARD) as technical director.

In 2000 he was named as Deputy General Manager in charge of the industrial production.

In 2007 he was in charge of the innovation team and several global accounts.

In 2014 he joined Givaudan as Operations Director & site manager

Since 2018, he held the position of Head of Operations Strategy in charge of tolling & process development for Givaudan Active Beauty